News & Updates

Use of medication is markedly different among older patients with inflammatory bowel disease (IBD), with more aminosalicylate monotherapy and less antitumour necrosis factor monotherapy than younger patients, according to a US study.

Supplementation with lutein/zeaxanthin instead of beta carotene is safe and does not contribute to an increase in lung cancer risk while having a potential beneficial effect on the risk of progression to late age-related macular degeneration (AMD), according to data from the Age-Related Eye Disease Study 2 (AREDS2) study.

In the phase II NEOBLADE* trial, the addition of the multikinase** inhibitor nintedanib to neoadjuvant chemotherapy (CT) consisting of gemcitabine and cisplatin failed to improve pathological complete response (pCR) and progression-free survival (PFS) in individuals with locally advanced muscle-invasive bladder cancer (MIBC).

The anaplastic lymphoma kinase (ALK) inhibitor ceritinib delivers favourable antitumour activity in ALK-mutated nonsmall cell lung cancer (NSCLC) patients with active brain metastases and/or leptomeningeal disease, according to the phase II ASCEND-7 trial.

Patients with psoriatic arthritis (PsA) with no prior exposure to biological disease-modifying antirheumatic drugs (bDMARDs) experience improvements in their condition when treated with bimekizumab, according to results of the phase III BE OPTIMAL trial.